CO4600644A1 - VACCINE AGAINST SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME - Google Patents

VACCINE AGAINST SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME

Info

Publication number
CO4600644A1
CO4600644A1 CO97010338A CO97010338A CO4600644A1 CO 4600644 A1 CO4600644 A1 CO 4600644A1 CO 97010338 A CO97010338 A CO 97010338A CO 97010338 A CO97010338 A CO 97010338A CO 4600644 A1 CO4600644 A1 CO 4600644A1
Authority
CO
Colombia
Prior art keywords
vaccine
virus
attenuated
respiratory syndrome
live
Prior art date
Application number
CO97010338A
Other languages
Spanish (es)
Inventor
Richard A Hesse
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24442410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4600644(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO4600644A1 publication Critical patent/CO4600644A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses

Abstract

La invención describe una vacuna y métodos para eltratamiento del síndrome reproductivo y respiratorio porcino. La vacuna se obtiene del agente viral NEB- 1-P94. Además, la invención describe un virus de vacuna con características fenotípicas que pueden distinguirse del virus de PRRS de tipo cimarrón. Depósito en la Asociación Americana de Cultivos Tipo No. VR-2525.La vacuna de acuerdo con la reivindicación 1 que se encuentra en forma viva, muerta o viva modificada (atenuada).La vacuna de acuerdo con a reivindicación 2 en la cual el agente viral es vivo modificado (atenuado) o se encuentra en forma líquida, congelada o desecada.La vacuna de acuerdo con la reivindicación 1 que contiene una cantidad de 104,0 a 109,0 TCID50 del virus de PRRS por ml.La vacuna de acuerdo con la reivindicación 1 en la cual el virus atenuado se puede distinguir de las formas de tipo cimarrón del virus en base a la falta de reactividad con el anticuerpo monoclonal SDOW17 y la falta de desarrollo eficiente en células macrófagos alveolares porcinas.Un método para proteger a un cerdo de la enfermedad clínica provocada por el virus del síndrome reproductivo y respiratorio porcino que comprende administrar una cantidad eficaz de la vacuna de la reivindicación 1 a un cerdo que necesita protección contra a enfermedad provocada por dicho virus.Un método de acuerdo con la reivindicación 6 en el cual dicha vacuna es administrada por vía oral, intranasal, intramuscular, intradérmica, intravenosa o subcutánea.The invention describes a vaccine and methods for the treatment of porcine reproductive and respiratory syndrome. The vaccine is obtained from the viral agent NEB-1-P94. Furthermore, the invention describes a vaccine virus with phenotypic characteristics that can be distinguished from the wild-type PRRS virus. Deposit in the American Culture Association Type No. VR-2525. The vaccine according to claim 1 found in live, dead or modified live (attenuated) form. The vaccine according to claim 2 in which the agent Viral is live modified (attenuated) or is in liquid, frozen or dried form. The vaccine according to claim 1 containing an amount of 104.0 to 109.0 TCID50 of the PRRS virus per ml. The vaccine according with claim 1 in which the attenuated virus can be distinguished from the wild type forms of the virus based on the lack of reactivity with the monoclonal antibody SDOW17 and the lack of efficient development in porcine alveolar macrophage cells. A method to protect a pig of the clinical disease caused by the porcine reproductive and respiratory syndrome virus comprising administering an effective amount of the vaccine of claim 1 to a pig in need of protection c Against disease caused by said virus. A method according to claim 6 in which said vaccine is administered orally, intranasally, intramuscularly, intradermally, intravenously or subcutaneously.

CO97010338A 1996-03-01 1997-02-26 VACCINE AGAINST SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME CO4600644A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60980696A 1996-03-01 1996-03-01

Publications (1)

Publication Number Publication Date
CO4600644A1 true CO4600644A1 (en) 1998-05-08

Family

ID=24442410

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97010338A CO4600644A1 (en) 1996-03-01 1997-02-26 VACCINE AGAINST SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME

Country Status (19)

Country Link
EP (1) EP0894007A1 (en)
JP (1) JP3135069B2 (en)
KR (1) KR100297537B1 (en)
CN (1) CN1165342C (en)
AR (1) AR006023A1 (en)
AU (1) AU2277497A (en)
BG (1) BG64693B1 (en)
BR (1) BR9708443B1 (en)
CA (1) CA2248182C (en)
CO (1) CO4600644A1 (en)
CZ (1) CZ273798A3 (en)
EE (1) EE04741B1 (en)
HU (1) HUP9901958A3 (en)
MY (1) MY115070A (en)
PL (1) PL328627A1 (en)
RU (1) RU2187333C2 (en)
SK (1) SK119498A3 (en)
WO (1) WO1997031651A1 (en)
ZA (1) ZA971663B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
NZ501264A (en) 1998-12-22 2001-09-28 Pfizer Prod Inc Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
PL204373B1 (en) 1999-03-08 2010-01-29 Boehringer Ingelheim Vetemendi Prrsv vaccines
WO2000065032A1 (en) 1999-04-22 2000-11-02 United States Department Of Agriculture Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
AR049924A1 (en) 2004-06-18 2006-09-13 Univ Minnesota IDENTIFICATION OF VIRALLY INFECTED AND VACCINATED ORGANISMS
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
HUE031018T2 (en) 2005-06-24 2017-06-28 Univ Minnesota PRRS viruses, infectious clones, mutants thereof, and methods of use
CN101612395B (en) * 2008-06-24 2012-02-08 扬州优邦生物制药有限公司 Method for producing blue-ear disease vaccine by culturing sensitive cell
AR078253A1 (en) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed METHODS TO REDUCE ANTIVIRICAL ACTIVITY IN PCV-2 COMPOSITIONS AND PCV-2 COMPOSITIONS WITH BETTER IMMUNOGENICITY
UA117272C2 (en) 2011-02-17 2018-07-10 Бьорінгер Інгельхайм Ветмедіка Гмбх NEW EUROPEAN PRRSV STRAIN
DK2675476T3 (en) 2011-02-17 2015-12-14 Boehringer Ingelheim Vetmed Process for producing PRRSV on a commercial scale
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
WO2013017570A1 (en) 2011-07-29 2013-02-07 Boehringer Ingelheim Vetmedica Gmbh Novel prrs virus inducing type i interferon in susceptible cells
KR101300528B1 (en) * 2011-10-05 2013-09-02 캔 테크놀로지스 인코포레이티드 Composition for prevention and treatment of Actinobacillus pleuropneumoniae infection
CN105073130A (en) 2013-03-15 2015-11-18 勃林格殷格翰动物保健公司 Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
EP4012025A1 (en) * 2020-12-10 2022-06-15 Univerzita Palackého v Olomouci Transport medium for samples containing nucleic acids and/or proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042830A (en) * 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
AU2684792A (en) * 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
FR2686097B1 (en) * 1992-01-14 1994-12-30 Rhone Merieux PREPARATION OF ANTIGENS AND MYSTERY DISEASE VIRUS VACCINES, ANTIGENS AND VACCINES OBTAINED FOR THE PREVENTION OF THIS DISEASE.
US5695766A (en) * 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
CZ289743B6 (en) * 1993-02-08 2002-03-13 Bayer Corporation Porcine reproductive and respiratory syndrome virus (PRRSV) isolate, process for growing PRRSV, tissue culture, process for preparing a vaccine and the vaccine containing the PRRSV isolate
ES2074950B1 (en) * 1993-09-17 1996-03-16 Iberica Cyanamid VACCINE FOR THE PREVENTION OF REPRODUCTIVE AND RESPIRATORY DISEASE OF THE SOW.
DK0676467T3 (en) * 1994-04-11 2002-01-21 Akzo Nobel Nv European vaccine strains of the porcine reproductive respiratory syndrome virus (PRRSV)
US5690940A (en) * 1995-06-21 1997-11-25 Regents Of The University Of Minnesota Low pathogencity PRRS live virus vaccines and methods of preparation thereof

Also Published As

Publication number Publication date
CZ273798A3 (en) 1999-02-17
KR19990087432A (en) 1999-12-27
EE04741B1 (en) 2006-12-15
HUP9901958A3 (en) 2000-04-28
ZA971663B (en) 1997-08-26
BG64693B1 (en) 2005-12-30
MY115070A (en) 2003-03-31
JP3135069B2 (en) 2001-02-13
AU2277497A (en) 1997-09-16
EP0894007A1 (en) 1999-02-03
BR9708443B1 (en) 2012-06-12
CN1216922A (en) 1999-05-19
BR9708443A (en) 1999-08-03
KR100297537B1 (en) 2001-10-26
HUP9901958A2 (en) 1999-10-28
MX9807083A (en) 1998-12-31
EE9800267A (en) 1999-02-15
SK119498A3 (en) 1999-07-12
CA2248182A1 (en) 1997-09-04
JPH11506122A (en) 1999-06-02
CA2248182C (en) 2004-04-20
RU2187333C2 (en) 2002-08-20
CN1165342C (en) 2004-09-08
WO1997031651A1 (en) 1997-09-04
BG102809A (en) 1999-05-31
PL328627A1 (en) 1999-02-15
AR006023A1 (en) 1999-07-21

Similar Documents

Publication Publication Date Title
CO4600644A1 (en) VACCINE AGAINST SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME
Zhao et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses
DE60045668D1 (en) Influenza virus vaccine composition
ES2170234T3 (en) VACCINE AGAINST PRRS VIRUS (SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME).
CO5611162A2 (en) METHODS TO PREVENT REPRODUCTIVE DISEASES IN VACCINE LIVESTOCK
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
ES2118815T3 (en) VIRUSES OF LA SEUDORRABIA, S-PRV-155, ATTENUATED AND OBTAINED BY GENETIC ENGINEERING AND ITS USES.
CO4980846A1 (en) A PHARMACEUTICAL COMPOSITION USED IN A METHOD FOR THE PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
ES2157522T3 (en) EUROPEAN VACCINE VIRUSES OF THE SWINE REPRODUCTIVE RESPIRATORY SYNDROME (PRRSV).
AR057695A1 (en) PROCEDURES FOR ADMINISTRATION OF VACCINES AGAINST FELIN CALCIVIRUS, AND TREATMENTS TO IMMUNIZE ANIMALS AGAINST FELINE PARVOVIRUS AND HERPES VIRUS FELINO
RU2001101426A (en) ATTENED VIRUSES WITH MINUS CHAIN WITH CHANGED ANTAGONISTIC ACTIVITY FOR INTERFERON FOR USE AS VACCINES AND PHARMACEUTICAL SUBSTANCES
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
RU2010117614A (en) AVIRULENT ADJUVANT LIVE VACCINE AGAINST MYCOPLASMA HYOPNEUMONIAE
CO5280094A1 (en) AN ANALOG OF A OR APP AND AN IMMUNOGENIC COMPOSITION THAT INCLUDES SUCH ANALOG
JP2002504317A5 (en)
EA200300023A1 (en) 3'-PROCEDURES 2'-DEOXY-β-L-NUCLEOSIDES
AR085272A1 (en) PRRSV CEPA (PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS) EUROPEAN
RU96119986A (en) VACCINE FOR PIG PREVENTION FROM RESPIRATORY OR REPRODUCTIVE DISEASES CONTAINING PARAGRIPPOUS VIRUSES
RU98118186A (en) VACCINE AGAINST REPRODUCTIVE AND RESPIRATORY SYNDROME IN PIG
ECSP024257A (en) OLD PROTEINS OF THE VIRUS DISEASE OF THE WHITE SPOT DISEASE IN THE SHRIMP AND USES OF THE SAME
JP2018537996A (en) Feline calicivirus vaccine
ATE516034T1 (en) METHOD FOR MODULATING THE IMMUNE RESPONSE IN AN INFECTED MAMMAL BY TRANSMUCOSAL ADMINISTRATION OF A MODULATING AGENT
ATE244578T1 (en) TREATMENT OF GASTRODUODENAL DISEASE CAUSED BY HELICOBACTER
Lee et al. Newly emerging human coronaviruses: animal models and vaccine research for SARS, MERS, and COVID-19
JP2023098935A5 (en)